Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Payor Coverage
Bluebird Bio signs state Medicaid agreement for SCD gene therapy
By
LabPulse.com staff writers
Bluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.
March 11, 2024
Report shows Medicare risked up to $888M in improper payments for molecular pathology test
By
Leo O'Connor
The HHS Office of Inspector General analyzed Medicare Part B claims associated with payments for more than 450,000 genetic tests billed under Current Procedural Terminology (CPT) code 81408.
June 23, 2023
Patients concerned about Medicare policy that limits coverage of noninvasive post-transplant tests
By
LabPulse.com staff writers
In a survey, 95% of patient participants said they believe that reduced coverage for noninvasive tests would negatively impact their post-transplant care.
May 12, 2023
MDxHealth nabs reimbursement for prostate cancer risk test
By
LabPulse.com staff writers
The firm's Select mdx test will now be reimbursed in the U.S. for Medicare patients who meet coverage conditions under a specific, foundational Local Coverage Determination (LCD).
April 20, 2023
For 2016 and 2017, Geisinger received at least $6.5M in overpayments from CMS: HHS OIG report
By
LabPulse.com staff writers
Based on estimates, Geisinger received millions in overpayments for 2016 and 2017 but Geisinger also disagreed with almost all findings outlined in a draft report, OIG said.
March 20, 2023
DermTech obtains melanoma testing coverage for additional 1.9 million people
By
LabPulse.com staff writers
The skin-based genomics test is a noninvasive way to enhance melanoma detection with a greater than 99% negative predictive value, DermTech said.
March 7, 2023
Medicare paid $704.2M for drug testing at risk of noncompliance with requirements
By
LabPulse.com staff writers
In an audit, the Office of Inspector General identified Medicare Part B payments for drug testing services that were at risk for noncompliance with Medicare requirements.
March 1, 2023
UnitedHealthcare increases coverage for Guardant360 CDx liquid biopsy test
By
LabPulse.com staff writers
The new policy coverage by UnitedHealthcare is in addition to coverage for the liquid biopsy CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.
February 8, 2023
DermTech melanoma assay recommended for coverage by military healthcare program
By
LabPulse.com staff writers
DermTech said the coverage recommendation makes the assay available to Tricare’s approximately nine million members and beneficiaries of the U.S. military health system.
January 11, 2023
Aspira Women’s Health announces milestones for expanded access to ovarian cancer risk test
By
LabPulse.com staff writers
The 2023 Omnibus Spending Bill contains language directing CMS to cover multimarker tests for ovarian cancer, increasing access to this testing; the expansion could encourage commercial insurers to adopt similar coverage policies.
December 27, 2022
Medicare policy increases access to noninvasive colorectal cancer tests: Exact Sciences
By
LabPulse.com staff writers
CMS is expanding coverage for certain colorectal cancer screening tests by reducing the minimum age payment and coverage limitation from 50 to 45 years.
December 20, 2022
Biodesix nabs positive coverage decisions from four private payors
By
LabPulse.com staff writers
The firm’s Nodify XL2 test will now be covered for enrollees of Blue Cross of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York.
December 19, 2022
Page 1 of 5
Next Page